Drug Profile
Maraciclatide
Alternative Names: 99mTc-maraciclatide; 99mTc-NC100692; GE-078; NC-100692; Tc-99m-NC100692; Tc99m-Maraciclatide; TcNC100692Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GE Healthcare
- Class Cyclic peptides; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cardiovascular disorders
- No development reported Breast cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Diagnosis) in United Kingdom (IV)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Diagnosis) in USA (IV)
- 11 Sep 2015 Clinical development is ongoing in USA and United Kingdom